Michael E Thase MD
Professor of Psychiatry, Director, Mood and Anxiety Program at Penn
Join to View Full Profile
3535 Market StPhiladelphia, PA 19104
Phone+1 215-746-6700
Fax+1 215-746-5155
Dr. Thase is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UPMC Medical EducationResidency, Psychiatry, 1979 - 1983
Ohio State University College of MedicineClass of 1979
Certifications & Licensure
PA State Medical License 1980 - 2026
NJ State Medical License 2022 - 2025
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013, 2016-2017
Clinical Trials
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Start of enrollment: 1998 Sep 01
- Cognitive Therapy for Treating Depression and Preventing Relapse Start of enrollment: 1999 Dec 01
- Cognitive Therapy Versus Medication Treatment for Preventing Depression Relapse Start of enrollment: 2003 Dec 01
Publications & Presentations
PubMed
- GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial.Michael E Thase, Brian Brennan, Rachael MacIsaac, Luca Pani, Velichka Valcheva
Psychopharmacology Bulletin. 2026-06-05 - 2 citationsGH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.Wieslaw J Cubala, Malek Bajbouj, Michael Bauer, Bernhard T Baune, Narcís Cardoner
JAMA Psychiatry. 2026-06-01 - The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD.David W Goodman, Rajnish Mago, Leslie Citrome, Holly A Swartz, Roger S McIntyre
European Neuropsychopharmacology. 2026-05-20
Journal Articles
- Opioid System Modulation with buprenorphine/samidorphan Combination for Major Depressive Disorder: Two Randomized Controlled StudiesMichael E Thase, Madhukar H Trivedi, Maurizio Fava, Nature
- American Psychiatric Association PublishingMichael Thase, MD, The American Journal of Psychiatry
- Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US VeteransJerome A Yesavage, Michael Thase, Steven D Forman, Amit Etkin, Mark S George, JAMA
Press Mentions
Psilocybin Under Consideration as Next Depression TreatmentSeptember 17th, 2025- Psychotherapy Can Be Readily Integrated into Brief “Med-Check” Psychiatry VisitsSeptember 17th, 2025
- Treatment for Anxiety: Medications and OptionsApril 6th, 2023
Grant Support
- VA Aripiprazole vs. Esketamine for Treatment of Depression VAST-D IIVA CONNECTICUT HEALTHCARE SYSTEM2021–2026
- 1/2-Efficacy Of Computer-Assisted Cognitive Behavior Therapy For DepressionNational Institute Of Mental Health2010–2012
- Prophylactic Cognitive Therapy For DepressionNational Institute Of Mental Health2007–2010
- Are Cognitive Therapy'S Antidepressant Effects Durable?National Institute Of Mental Health2004–2007
- Revamp Follow-Up StudyNational Institute Of Mental Health2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
